

# Pharmacology of Bacterial Protein Synthesis Inhibitors



صلى الله عليه وسلم  
رعد صاقد  
انتدكر اذ دره تفتحه

Dr. Nashwa Aborayah

Associate professor of clinical and experimental pharmacology

Mu'tah University- Faculty of Medicine

JORDAN 2024/2025





# Objectives

- 1- Protein synthesis in bacterial ribosomes
- 2- Mechanism of action of protein synthesis inhibitors antibiotics
- 3- Classification of protein synthesis inhibitors
- 4- Aminoglycosides
- 5- Macrolides
- 6- Tetracyclines
- 7- Chloramphenicol
- 8- Clindamycin


# Ribosomes: site of protein synthesis

- **Prokaryotic ribosomes are 70S:**
- Large subunit: 50 S
  - 33 polypeptides
- Small subunit: 30 S
  - 21 polypeptides
- **Eukaryotic are 80S**
- **Selective toxicity:**
- **acting at the ribosomal level taking the advantage of major differences prokaryotic and eukaryotic ribosome structure**







## Bacteria protein synthesis



Aminoglycoside-treated bacterial cell



# Classification

## TETRACYCLINES 1

*Demeclocycline* DECLOMYCIN

*Doxycycline* VIBRAMYCIN

*Minocycline* MINOCIN

*Tetracycline* SUMYCIN

## GLYCYLCYCLINES 2

*Tigecycline* TYGACIL

## AMINOGLYCOSIDES 3

*Amikacin* AMIKIN, OTHERS

*Gentamicin* GARAMYCIN → (بدون)

*Neomycin* NEO-FRADIN

*Streptomycin* STREPTOMYCIN

Go to New Strept

## MACROLIDES/KETOLIDES 4

*Azithromycin* ZITHROMAX

*Clarithromycin* BIAXIN

*Erythromycin* E-MYCIN

*Telithromycin* KETEK

## OTHERS 5

*Chloramphenicol* CHLOROMYCETIN

*Clindamycin* CLEOCIN

*Linezolid* ZYVOX

*Quinupristin/Dalfopristin* SYNERCID

UT → TB.  
Unitary  
Work inf.

+ Cipramycin

(بدون)  
= بدون

	<b>Aminoglycosides (cidal)</b>	<b>Macrolides (static) Moderate spectrum</b>	<b>Chloramphenicol (Static- broad spectrum)</b>	<b>Clindamycin (static)</b>	<b>Tetracyclines (static- broad spectrum)</b>
<b>PDS</b>	Irreversible binding to 30S subunit: misreading of mRNA	Binding of 50S subunit: (weak reversible binding) Increasing concentration turns the drug into cidal <b>MW&gt;500</b>	Binding (weak) to 50S subunit <b>MW&lt;500, only 2 –OH groups, 2 Cl atoms</b> <b>Not used nowadays except topical for eye infections</b>	Binding to 50 S subunit (as erythromycin) at the same binding site <b>MW &lt;500</b>	Reversible (weak) binding to 30S subunit <b>MW&lt;500 except tigecycline (parenteral)</b> <b>Containing –OH groups, least in minocycline</b>
<b>PKs</b>	<ul style="list-style-type: none"> <li>Not absorbed orally</li> <li>Parenteral</li> <li>Not pass BBB</li> <li>Can NOT pass placenta and breast milk</li> <li>Not metabolized</li> <li>Excreted unchanged in urine: active in alkaline urine</li> <li>N.B.</li> </ul> <p><b>Synergy</b> - The aminoglycosides synergize with <math>\beta</math>-lactam antibiotics. The <math>\beta</math>-lactams inhibit cell wall synthesis and thereby increase the permeability of the aminoglycosides.</p>	<ul style="list-style-type: none"> <li>Poor oral absorption, affected by food (on empty stomach)</li> <li>Not pass BBB</li> <li>Pass placenta but not teratogenic: <b>safe in pregnancy: erythromycin, zithromycin</b></li> <li>Pass to most body fluids in good concentration (prostate)</li> <li><b>Concentrated in macrophages and polymorphs (long biological half life)</b></li> <li>Metabolism: liver</li> <li>Excretion: bile, enterohepatic circulation</li> <li><b><u>Membres:</u> erythromycin, clarithromycin, azithromycin, spiramycin</b></li> </ul>	<ul style="list-style-type: none"> <li>Well-absorbed, not affected by food</li> <li>Pass BBB: <b>2<sup>nd</sup> choice in meningitis</b></li> <li>Widely distributed: high Vd</li> <li>Pass placenta, in breast milk</li> <li>Metabolized by glucuronidation in liver: glucuronyl transferase phase II</li> <li>Excreted in urine: inactive metabolites</li> </ul>	<ul style="list-style-type: none"> <li>Rapid complete oral absorption</li> <li>pass BBB in small amounts <b>enough to treat meningitis</b></li> <li>Penetrates bone, tissue fluids including prostate</li> <li>Pass placenta: <b>not teratogenic</b></li> <li>Metabolism: liver</li> <li>Excretion: bile</li> </ul>	<ul style="list-style-type: none"> <li>Partially absorbed</li> <li>Absorption decreased with: food, milk, antacid, iron (binds to heavy metals)</li> <li>Incomplete passage to BBB</li> <li>Concentrated in bone, teeth</li> <li>Pass placenta (teratogenic) and breast milk (<b>high affinity to Ca</b>) <b>≠ pregnancy, lactation, children&lt;8 y</b></li> <li>Metabolism: extensive in liver</li> <li>Excreted in urine 80% (inactive) more than in bile (enterohepatic circulation)</li> <li>N.B. doxycycline and minocycline : nearly complete oral absorption, 50% renal excretion, 50% in bile: can be used in renal impairment</li> </ul>





**Lyme disease**



**Rocky mountain spotted fever**



# Q FEVER

## symptoms



**HEADACHE**




**FEVER**



**COUGH**



**DIARRHEA**



**STOMACH PAIN**



**VOMITING**



**WEIGHT LOSS**



**FATIGUE**



**CHILLS**




**CHEST PAIN**



**SWEATS**

## Teratogenicity of Chloramphenicol

- There are no literature reports linking the use of this drug in pregnancy to birth defects
- **Its administration** late in pregnancy has been associated with adverse effects in the neonate (**grey baby syndrome**).
- **Low capacity to glucoronyl transferase enzyme and underdeveloped renal function**  $\Rightarrow$  a decreased ability to excrete the drug  $\Rightarrow$  drug accumulates to levels that interfere with the function of mitochondrial ribosomes  $\ggggg$  poor feeding, depressed breathing, cardiovascular collapse, cyanosis ( $\Rightarrow$  "grey baby") and death.



## **References**

***Lippincott's Illustrated Review***

*Pharmacology, 8<sup>th</sup> edition*

***Lippincott Williams & Wilkins***

***Katzung*** by Anthony Trevor, Bertram Katzung, and Susan Masters . 16<sup>th</sup>  
edition McGraw Hill,

***Rang & Dale's Pharmacology:*** by Humphrey P. Rang ; James M.  
Ritter ; Rod Flower Churchill Livingstone; 10<sup>th</sup> edition

Thank you 